BR112021000347A2 - Proteína de fusão variante pd1-4-1bbl e métodos de uso da mesma - Google Patents
Proteína de fusão variante pd1-4-1bbl e métodos de uso da mesma Download PDFInfo
- Publication number
- BR112021000347A2 BR112021000347A2 BR112021000347-9A BR112021000347A BR112021000347A2 BR 112021000347 A2 BR112021000347 A2 BR 112021000347A2 BR 112021000347 A BR112021000347 A BR 112021000347A BR 112021000347 A2 BR112021000347 A2 BR 112021000347A2
- Authority
- BR
- Brazil
- Prior art keywords
- amino acid
- acid sequence
- seq
- 1bbl
- fusion protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696365P | 2018-07-11 | 2018-07-11 | |
| US62/696,365 | 2018-07-11 | ||
| US201862786599P | 2018-12-31 | 2018-12-31 | |
| US62/786,599 | 2018-12-31 | ||
| PCT/IL2019/050782 WO2020012485A1 (en) | 2018-07-11 | 2019-07-11 | Pd1-4-1bbl variant fusion protein and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021000347A2 true BR112021000347A2 (pt) | 2021-04-13 |
Family
ID=69142114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021000347-9A BR112021000347A2 (pt) | 2018-07-11 | 2019-07-11 | Proteína de fusão variante pd1-4-1bbl e métodos de uso da mesma |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12286466B2 (https=) |
| EP (1) | EP3820887A4 (https=) |
| JP (1) | JP2021531265A (https=) |
| KR (1) | KR20210044221A (https=) |
| CN (1) | CN112543767B (https=) |
| AU (1) | AU2019301315A1 (https=) |
| BR (1) | BR112021000347A2 (https=) |
| CA (1) | CA3104778A1 (https=) |
| IL (1) | IL280102A (https=) |
| MX (1) | MX2021000047A (https=) |
| SG (1) | SG11202013170RA (https=) |
| WO (1) | WO2020012485A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| RU2769769C2 (ru) | 2017-01-05 | 2022-04-05 | Кахр Медикал Лтд. | СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ |
| CN110536693B (zh) | 2017-01-05 | 2023-12-22 | 卡尔医学有限公司 | Pd1-41bbl融合蛋白及使用其的方法 |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| KR102171766B1 (ko) * | 2018-02-02 | 2020-10-29 | 주식회사 뉴라클제네틱스 | Pd-l1 결합력이 증대된 pd-1 변이체 |
| EP3820887A4 (en) | 2018-07-11 | 2022-04-20 | KAHR Medical Ltd. | Pd1-4-1bbl variant fusion protein and methods of use thereof |
| KR102945860B1 (ko) | 2018-07-11 | 2026-03-31 | 카 메디컬 리미티드 | SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법 |
| US20220267409A1 (en) * | 2019-07-11 | 2022-08-25 | Kahr Medical Ltd. | Heterodimers and methods of use thereof |
| WO2021137231A1 (en) * | 2019-12-31 | 2021-07-08 | Kahr Medical Ltd. | Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same |
| US20230048361A1 (en) * | 2019-12-31 | 2023-02-16 | Kahr Medical Ltd. | Methods of culturing t cells and uses of same |
| US20230287081A1 (en) * | 2020-04-16 | 2023-09-14 | Nantong Yichen Biopharma. Co. Ltd. | PD-1 mutant polypeptide and preparation and application thereof |
| CN116615442A (zh) * | 2020-09-08 | 2023-08-18 | 优特力克斯有限公司 | 程序性细胞死亡1多肽变体 |
| KR20220061644A (ko) * | 2020-11-06 | 2022-05-13 | 주식회사 제넨바이오 | Pd-l1 및 il-10의 융합단백질을 유효성분으로 하는 이식거부반응 치료용 약학적 조성물 |
| CN114369581B (zh) * | 2021-12-30 | 2023-10-20 | 杭州医学院 | 一种具有抗肿瘤免疫功能重组腺病毒、制备方法及应用 |
| CN114940710B (zh) * | 2022-06-07 | 2023-09-26 | 恺佧生物科技(上海)有限公司 | 一种提高重组人psma蛋白表达的方法 |
| CN120202214A (zh) * | 2022-10-28 | 2025-06-24 | Fbd生物制品有限公司 | 经工程改造的4-1bbl变体及其使用方法 |
| WO2025128263A1 (en) * | 2023-12-15 | 2025-06-19 | Pharmaessentia Corporation | Anti-pd-1 monoclonal antibody and methods of preparation thereof |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5287386A (en) | 1991-03-27 | 1994-02-15 | Thinking Machines Corporation | Differential driver/receiver circuit |
| US5674704A (en) * | 1993-05-07 | 1997-10-07 | Immunex Corporation | Cytokine designated 4-IBB ligand |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6046048A (en) | 1996-01-09 | 2000-04-04 | Genetech, Inc. | Apo-2 ligand |
| JP2002508962A (ja) | 1998-01-15 | 2002-03-26 | ジェネンテク・インコーポレイテッド | Ａｐｏ−２リガンド |
| IL150571A0 (en) | 2000-01-03 | 2003-02-12 | Tr Associates L L C | Novel chimeric proteins and methods for using the same |
| AU3087801A (en) | 2000-02-04 | 2001-08-14 | Molecular Dynamics Inc | Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| ES2394018T3 (es) | 2001-11-27 | 2013-01-15 | Ucb Pharma S.A. | Procedimientos para el diagnóstico y el tratamiento de cánceres derivados de células epiteliales |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| KR20050082389A (ko) | 2004-02-18 | 2005-08-23 | 메덱스젠 주식회사 | 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물 |
| US7142018B2 (en) | 2004-06-08 | 2006-11-28 | Transmeta Corporation | Circuits and methods for detecting and assisting wire transitions |
| US7279925B1 (en) | 2005-03-10 | 2007-10-09 | Cypress Semiconductor Corp. | Capacitive feedforward circuit, system, and method to reduce buffer propagation delay |
| JP2006345852A (ja) * | 2005-06-16 | 2006-12-28 | Virxsys Corp | 抗体複合体 |
| SG10202112838YA (en) | 2008-04-09 | 2021-12-30 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases |
| CA2729351C (en) | 2008-06-30 | 2017-01-24 | University Of Pennsylvania | Fn14/trail fusion proteins |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| WO2010070047A1 (en) | 2008-12-19 | 2010-06-24 | Novartis Ag | Soluble polypeptides for use in treating autoimmune and inflammatory disorders |
| HRP20150553T1 (hr) | 2009-05-15 | 2015-08-28 | University Health Network | Sastavi i metode za lijeäśenje hematoloških maligniteta ciljajuä†i sirp - cd47 interakciju |
| CA3253628A1 (en) | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| AU2011309689B2 (en) | 2010-09-28 | 2015-01-15 | Hadasit Medical Research Services & Development Ltd. | Compositions and methods for treatment of hematological malignancies |
| US8675439B2 (en) | 2011-10-12 | 2014-03-18 | Taiwan Semiconductor Manufacturing Co., Ltd. | Bit line voltage bias for low power memory design |
| US9926364B2 (en) | 2011-11-03 | 2018-03-27 | Argen-X N.V. | Chimeric human-llama antigens and methods of use |
| ES2816647T3 (es) | 2012-01-17 | 2021-04-05 | Univ Leland Stanford Junior | Reactivos SIRP-alfa de alta afinidad |
| WO2013112986A1 (en) | 2012-01-27 | 2013-08-01 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
| CA2868408A1 (en) | 2012-03-29 | 2013-10-03 | Aurigene Discovery Technologies Limited | Immunomodulating cyclic compounds from the bc loop of human pd1 |
| PL3489254T3 (pl) | 2012-04-30 | 2023-01-30 | Biocon Limited | Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania |
| EP2730588A1 (en) | 2012-11-12 | 2014-05-14 | Intelectys | Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof |
| EP3508215A3 (en) | 2012-12-03 | 2019-10-02 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
| WO2014106839A1 (en) | 2013-01-01 | 2014-07-10 | Kahr Medical Ltd. | Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof |
| WO2014121093A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| EP2995626B1 (en) | 2013-05-06 | 2018-07-11 | China Pharmaceutical University | Bifunctional fusion proteins to inhibit angiogenesis in tumour microenvironment and to activate adaptive immune responses and the genes and uses thereof |
| JP6355032B2 (ja) | 2014-03-24 | 2018-07-11 | イミューンオンコ バイオファーマシューティカルズ （シャンハイ） カンパニー リミテッド | 新規組換え二機能性融合タンパク質、それらの調製および使用 |
| PT3177640T (pt) * | 2014-08-08 | 2020-08-31 | Univ Leland Stanford Junior | Agentes pd-1 de alta afinidade e métodos de utilização |
| WO2016023001A1 (en) | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| PL3180363T3 (pl) | 2014-08-15 | 2020-02-28 | Merck Patent Gmbh | Białka fuzyjne immunoglobulin sirp-alfa |
| EP3012271A1 (en) | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| EP3224275B1 (en) * | 2014-11-14 | 2020-03-04 | F.Hoffmann-La Roche Ag | Antigen binding molecules comprising a tnf family ligand trimer |
| CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| CN118271463A (zh) | 2014-12-05 | 2024-07-02 | 纪念斯隆-凯特琳癌症中心 | 靶向g-蛋白偶联受体的嵌合抗原受体及其用途 |
| AU2016227322A1 (en) | 2015-03-03 | 2017-09-21 | Kahr Medical Ltd | Dual signaling protein (DSP) fusion proteins, and methods of using thereof for treating diseases |
| EP3973980A1 (en) | 2015-03-31 | 2022-03-30 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a trimeric tnf family ligand |
| CN106146670B (zh) | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术（上海）有限公司 | 一种新的重组双功能融合蛋白及其制备和应用 |
| CN114425077A (zh) | 2015-05-18 | 2022-05-03 | 起源生物医药公司 | Sirp多肽组合物和使用方法 |
| WO2017012770A1 (en) | 2015-07-23 | 2017-01-26 | Ratiopharm Gmbh | Acid addition salts of filgotinib |
| HUE068868T2 (hu) | 2015-07-30 | 2025-02-28 | Macrogenics Inc | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások |
| AR105520A1 (es) * | 2015-07-30 | 2017-10-11 | Macrogenics Inc | Moléculas de unión a pd-1 y métodos de uso de las mismas |
| EA034582B1 (ru) | 2015-08-07 | 2020-02-21 | АЭлЭкс ОНКОЛОДЖИ ИНК. | Конструкции варианта sirp-альфа и их применение |
| AU2016304794B2 (en) | 2015-08-07 | 2021-07-15 | ALX Oncology Inc. | Constructs having a SIRP-alpha domain or variant thereof |
| JP6981973B2 (ja) | 2015-10-01 | 2021-12-17 | ヒート バイオロジクス，インコーポレイテッド | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 |
| EP3364995B1 (en) | 2015-10-23 | 2021-08-04 | Apogenix AG | Single-chain cd27-receptor agonist proteins |
| WO2017152132A1 (en) | 2016-03-04 | 2017-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of identifying and treating immune checkpoint inhibitor-responsive neoplasms |
| EP3433269B1 (en) * | 2016-03-23 | 2023-09-27 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| CN109715808A (zh) * | 2016-04-15 | 2019-05-03 | 诺华股份有限公司 | 用于选择性蛋白质表达的组合物和方法 |
| EP3243832A1 (en) | 2016-05-13 | 2017-11-15 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety |
| TW201741337A (zh) | 2016-05-13 | 2017-12-01 | 麥迪紐有限責任公司 | ＣＤ４０Ｌ-Ｆｃ融合多肽及其使用方法 |
| AU2017272875B2 (en) | 2016-06-03 | 2023-10-19 | Invectys | Anti HLA-G specific antibodies |
| CN107586342A (zh) | 2016-07-08 | 2018-01-16 | 生命序有限公司 | 重组免疫检查点受体及其应用 |
| CN106267188B (zh) | 2016-08-15 | 2025-06-17 | 深圳大学 | 小分子免疫激动剂偶联pd-1抗体的新型抗体及其在抗肿瘤中的应用 |
| CN107868791B (zh) | 2016-09-26 | 2021-11-23 | 阿思科力(苏州)生物科技有限公司 | 一种加强型Slit2 CAR-T和CAR-NK细胞制备方法和应用 |
| HRP20211703T1 (hr) | 2016-11-02 | 2022-02-04 | Jounce Therapeutics, Inc. | Protutijela protiv pd-1 i njihova upotreba |
| TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| AU2017380981B2 (en) | 2016-12-19 | 2025-01-30 | F. Hoffmann-La Roche Ag | Combination therapy with targeted 4-1BB (CD137) agonists |
| CN110536693B (zh) * | 2017-01-05 | 2023-12-22 | 卡尔医学有限公司 | Pd1-41bbl融合蛋白及使用其的方法 |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| RU2769769C2 (ru) | 2017-01-05 | 2022-04-05 | Кахр Медикал Лтд. | СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ |
| CN107857819A (zh) | 2017-07-03 | 2018-03-30 | 江苏西迪尔生物技术有限公司 | 多功能融合蛋白及其应用 |
| JP2021500902A (ja) | 2017-11-01 | 2021-01-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 新規ｔｎｆファミリーリガンド三量体含有抗原結合分子 |
| KR102945860B1 (ko) | 2018-07-11 | 2026-03-31 | 카 메디컬 리미티드 | SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법 |
| EP3820887A4 (en) | 2018-07-11 | 2022-04-20 | KAHR Medical Ltd. | Pd1-4-1bbl variant fusion protein and methods of use thereof |
| US20210301020A1 (en) | 2018-07-24 | 2021-09-30 | Amgen Inc. | Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors |
| EP3908664A4 (en) | 2019-01-07 | 2023-01-25 | Thomas Jefferson University | MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USES |
| TWI760751B (zh) | 2019-05-29 | 2022-04-11 | 美商美國禮來大藥廠 | Tigit及pd-1/tigit-結合分子 |
| CN110128550B (zh) | 2019-05-30 | 2023-01-13 | 南京惟亚德生物医药有限公司 | 一种新型的同时阻断免疫检查点pd-l1和tigit的复制型溶瘤腺病毒和应用 |
| US20220267409A1 (en) | 2019-07-11 | 2022-08-25 | Kahr Medical Ltd. | Heterodimers and methods of use thereof |
| SE2050035A1 (en) | 2020-01-16 | 2021-07-17 | Holmbergs Safety System Holding Ab | Belt buckle for a safety belt in a child restraint system |
| US20240076346A1 (en) | 2021-01-13 | 2024-03-07 | Kahr Medical Ltd. | Type i membrane proteins heterodimers and methods of use thereof |
| US20250051410A1 (en) | 2021-12-23 | 2025-02-13 | Kahr Medical Ltd. | Lilrb polypeptides and uses thereof |
-
2019
- 2019-07-11 EP EP19833260.3A patent/EP3820887A4/en active Pending
- 2019-07-11 AU AU2019301315A patent/AU2019301315A1/en not_active Abandoned
- 2019-07-11 CA CA3104778A patent/CA3104778A1/en active Pending
- 2019-07-11 KR KR1020217004309A patent/KR20210044221A/ko not_active Ceased
- 2019-07-11 CN CN201980052864.9A patent/CN112543767B/zh active Active
- 2019-07-11 JP JP2021500820A patent/JP2021531265A/ja not_active Ceased
- 2019-07-11 US US17/258,220 patent/US12286466B2/en active Active
- 2019-07-11 SG SG11202013170RA patent/SG11202013170RA/en unknown
- 2019-07-11 BR BR112021000347-9A patent/BR112021000347A2/pt not_active IP Right Cessation
- 2019-07-11 MX MX2021000047A patent/MX2021000047A/es unknown
- 2019-07-11 WO PCT/IL2019/050782 patent/WO2020012485A1/en not_active Ceased
-
2021
- 2021-01-11 IL IL280102A patent/IL280102A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3104778A1 (en) | 2020-01-16 |
| EP3820887A1 (en) | 2021-05-19 |
| AU2019301315A1 (en) | 2021-02-11 |
| IL280102A (en) | 2021-03-01 |
| MX2021000047A (es) | 2021-05-12 |
| CN112543767B (zh) | 2024-05-31 |
| WO2020012485A9 (en) | 2020-04-30 |
| KR20210044221A (ko) | 2021-04-22 |
| WO2020012485A1 (en) | 2020-01-16 |
| JP2021531265A (ja) | 2021-11-18 |
| US20210284711A1 (en) | 2021-09-16 |
| CN112543767A (zh) | 2021-03-23 |
| SG11202013170RA (en) | 2021-01-28 |
| EP3820887A4 (en) | 2022-04-20 |
| US12286466B2 (en) | 2025-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12286466B2 (en) | PD1-4-1BBL variant fusion protein and methods of use thereof | |
| US20250163133A1 (en) | SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF | |
| US20240010700A1 (en) | Pd1-41bbl fusion protein and methods of use thereof | |
| US20220267409A1 (en) | Heterodimers and methods of use thereof | |
| AU2018205890B2 (en) | A sirpalpha-41BBL fusion protein and methods of use thereof | |
| US20230220040A1 (en) | Pd1-cd70 fusion protein and methods of use thereof | |
| US20240076346A1 (en) | Type i membrane proteins heterodimers and methods of use thereof | |
| IL313778A (en) | Lilrb polypeptides and uses thereof | |
| HK40017122B (en) | A pd1-41bbl fusion protein and methods of use thereof | |
| HK40017122A (en) | A pd1-41bbl fusion protein and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2840 DE 10/06/2025. |